Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.
Type:
Grant
Filed:
October 3, 2007
Date of Patent:
April 3, 2012
Assignee:
diaDexus, Inc.
Inventors:
Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
Type:
Grant
Filed:
March 17, 2010
Date of Patent:
April 3, 2012
Assignee:
Oncolytics Biotech Inc.
Inventors:
Donald Morris, Bradley G. Thompson, Matthew C. Coffey
Abstract: The present invention relates to novel prostate specific nucleic acid molecules and polypeptides and related methods for diagnosing or predicting susceptibility to a prostate neoplastic condition.
Abstract: The disclosure provides methods of identifying and making compounds and pharmaceutical compositions containing the compounds that inhibit the interaction between MUC1 and an IKK. The disclosure also provides in vivo and in vitro methods of inhibiting such an interaction. Also embraced by the disclosure are in vitro and in vivo methods of inhibiting the IKK/NF-?B pathway in cells expressing MUC1. The compounds, compositions, and methods of the disclosure are generally useful in the treatment of various cancers, inflammatory (e.g., autoimmune disorders), and transplant rejection.
Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
Type:
Grant
Filed:
February 15, 2008
Date of Patent:
February 14, 2012
Assignee:
The Board of Trustees of Southern Illinois University
Abstract: The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
Type:
Grant
Filed:
October 21, 2009
Date of Patent:
January 17, 2012
Assignee:
Board of Regents, The University of Texas System
Inventors:
Maher Albitar, Elihu H. Estey, Hagop M. Kantarjian, Francis J. Giles, Michael J. Keating
Abstract: Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed in the majority of breast cancers, and claudins 3 and 4 are overexpressed. The methods of treatment involve the use of Clostridium perfringens enterotoxin (or a variant thereof) to lyse metastatic cancer cells in the brain and bone that overexpress claudins 3 and 4.
Type:
Grant
Filed:
March 7, 2008
Date of Patent:
January 10, 2012
Assignee:
The Johns Hopkins University
Inventors:
Saraswati V. Sukumar, Scott L. Kominsky
Abstract: The present invention discloses the protease stratum corneum chymotryptic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.
Type:
Grant
Filed:
October 9, 2007
Date of Patent:
January 3, 2012
Assignee:
Board of Trustees of the University of Arkansas
Inventors:
Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin
Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
Abstract: Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.
Type:
Grant
Filed:
April 6, 2007
Date of Patent:
December 6, 2011
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services